Capricor Therapeutics (NASDAQ:CAPR) Earns Outperform Rating from Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report issued on Monday morning, Benzinga reports. The brokerage currently has a $15.00 target price on the biotechnology company’s stock.

CAPR has been the subject of several other reports. HC Wainwright reiterated a buy rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, September 17th. Cantor Fitzgerald restated an overweight rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Maxim Group reiterated a buy rating and set a $12.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics has a consensus rating of Moderate Buy and an average price target of $22.60.

Capricor Therapeutics Stock Up 13.6 %

NASDAQ:CAPR opened at $10.34 on Monday. Capricor Therapeutics has a twelve month low of $2.68 and a twelve month high of $12.87. The firm has a market capitalization of $336.46 million, a price-to-earnings ratio of -11.88 and a beta of 3.92. The stock’s 50 day moving average price is $4.59 and its two-hundred day moving average price is $5.25.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. As a group, analysts anticipate that Capricor Therapeutics will post -1.14 earnings per share for the current year.

Insider Activity at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after acquiring an additional 200,499 shares during the period. Jump Financial LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $258,000. BNP Paribas Financial Markets bought a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $40,000. Main Street Financial Solutions LLC grew its position in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Capricor Therapeutics during the 2nd quarter worth $426,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.